Alterity Therapeutics (ATHE) Cash & Equivalents (2009 - 2025)

Alterity Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $32.3 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 988.88% year-over-year to $32.3 million; the TTM figure through Dec 2025 stood at $32.3 million (up 988.88% YoY), while the FY2025 annual figure was $21.2 million, up 154.95% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $32.3 million, up from $21.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $32.3 million in Q4 2025, with the low at $126388.8 in Q2 2024.
• The 5-year median for Cash & Equivalents is $21.4 million (2021), against an average of $16.3 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 99.37% in 2023, then jumped 16702.03% in 2025.
• Alterity Therapeutics' Cash & Equivalents stood at $27.0 million in 2021, then slipped by 15.16% to $22.9 million in 2022, then plunged by 55.1% to $10.3 million in 2023, then sank by 71.11% to $3.0 million in 2024, then soared by 988.88% to $32.3 million in 2025.
• Business Quant data shows ATHE's Cash & Equivalents at $32.3 million in Q4 2025, $21.2 million in Q2 2025, and $3.0 million in Q4 2024.